VITAL European Project Kicks Off

Recently, the EU-sponsored Vaccines and InfecTious diseases in the Ageing popuLation (VITAL) project was launched. VITAL will address – in a public-private consortium – the challenges of infections in the elderly and the potential of infection prevention by vaccination.

Within the VITAL project, which will run from 2019-2023, University Medical Center (UMC) Utrecht will be the managing entity and scientific lead. The € 12.4 million project is sponsored by the European Union’s Innovative Medicines Initiative (IMI) with a grant of € 5.5 million which will be matched by grants in total of € 6.9 million from the European Federation of Pharmaceutical Industries Associations (EFPIA). The consortium academic leader is prof. dr. Debbie van Baarle, professor of Immunology of Vaccinations at UMC Utrecht and Head of the Department of Immune Mechanisms at the Centre for Immunology of Infectious Diseases and Vaccines at the National Institute of Health and the Environment (RIVM) in the Netherlands.

Multidisciplinary approach

Through a multidisciplinary public-private approach, VITAL will generate health, economic and societal benefits by mapping the disease burden of infectious diseases to be prevented by vaccines, Investigate immunity to infections and vaccinations in the aging population, calculate the clinical and economic consequences of possible vaccination strategies in different age and risk groups, and develop teaching tools for stakeholders.

The program is in line with recent recommendations from the European Council to strengthen cooperation against vaccine-preventable diseases by working on cross-border vaccination programs and develop research and development studies for better understanding the benefit of life-long vaccination impact[1].

Debbie van Baarle explains: “An aging immune system is known to cause increased infection rates in elderly people. Prevention of infectious diseases in the elderly through vaccination is a requirement to promote healthy ageing in this growing population. Our main challenge, in close collaboration with our EFPIA partners, is to overcome the reduced immune responsiveness of this age group by improving the efficacy of vaccines and to identify new vaccination strategies to protect elderly people from infectious diseases.”

Burden of infectious diseases

Due to demographic developments, the population of elderly increases in size every year. Older people are more vulnerable to infectious diseases because their immune system becomes weaker with increasing age. As a consequence, an increasing burden of infections in the elderly is observed. Avoiding such infections by vaccination should delay, reduce, or avoid the exposure to institutionalized health care. In order to achieve optimal vaccination strategies for elderly or better protect elderly against infectious diseases, better insights are needed on how the overall process of ageing, exposure to infection, and immune response to vaccination, is developing and evolving.

Public-private Partnership

The partners in the international VITAL project include 7 academic research groups, 7 public health institutes, 3 private consultancy partners and 7 pharmaceutical industries with long-standing experience in epidemiology, health economy, clinical trials, immunology and public health.

Project details

Name: VITAL – Vaccines and InfecTious diseases in the Ageing popuLation
Start date: January 1, 2019
Duration: 60 months
Budget: €12.4mio
Coordination: University Medical Center (UMC) Utrecht

VITAL partners
Academic research groups: University Medical Center Utrecht (the Netherlands), University Medical Center Groningen (the Netherlands), University of Innsbruck (Austria), Imperial College London (United Kingdom), University College London (United Kingdom), University of Ferrara (Italy), University Jean Monnet (France)

Public health institutes: National Institute for Public Health and the Environment (the Netherlands), Norwegian Institute for Public Health (Norway), INSERM: French National Institute of Health and Medical Research (France), Statens Serum Institute (Denmark), Centre National de la Recherche Scientifique (France), Instituto Superiore di Sanita (Italy), FISABIO: Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valencian (Spain)

Private partners: P95 (Belgium), Syreon Health Institute (Hungary), Mihailovic Health Analytics (Serbia), Glaxo SmithKline Biologicals (Belgium), Pfizer (United Kingdom), Sanofi Pasteur (France), Merck Sharp & Dohme, (USA), Janssen Vaccines & Prevention (the Netherlands), bioMerieux (France), Vaccines Europe/EFPIA.


Source: HollandBIO

‹ News overview